Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Alle Kategorien

Lalique Group strengthens its leadership » Report
Lalique Group verstärkt die Führung » Report
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) » Report
Roche: New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma » Report
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting » Report
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe Hemophilia A » Genentech
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A » Report
+++ ein schönes Wochenende, have a great weekend! +++
Redaktionsschluss
Warteck Invest: Personelle Veränderungen im Verwaltungsrat an der kommenden Generalversammlung vom 29. Mai 2024 » Report
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment » Genentech
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation » Genentech
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment » Report
Aumento delle previsioni di utile per l'esercizio 2023 e cambio del Consiglio di Amministrazione di IVF HARTMANN Holding AG » Report
Augmentation des prévisions de résultat pour l'exercice 2023 et changement au sein du conseil d'administration d'IVF HARTMANN Holding AG » Report
Erhöhung der Ergebnisprognose für das Geschäftsjahr 2023 sowie Änderung im Verwaltungsrat der IVF HARTMANN Holding AG » Report
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation » Report
GUTEN ABEND: DAILY SMI +0,95% 11'071 SMI Top CFR +2,6% LOGN +2,1% UBSG +1,8% ROG +1,5% SLHN +1,4% ABBN +1,3% Flop SCMN -0,2% ZURN SIKA ALC +0,1% LONN SREN +0,2% +++ VSMI -6,81% 10.78 (11.57) +++ DAX +0,78% 16'759 +++ Strasse gut gehalten +++ ein schönes Wochenende, have a great weekend!
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions » Report
cash Insider: Börsenwoche im Schnelldurchlauf - Schweizer Aktienmarkt: Gewinner raus, Verlierer rein? Der cash Insider kommentiert die wichtigsten Börsenereignisse. Diese Woche unter anderem: Eine Gewinnwarnung nach der nächsten, Norwegens Staatsfonds ist antizyklisch unterwegs - Und: ZKB versucht sich mal wieder an AMS. » cash